Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$26.97 USD

26.97
2,911,983

-0.20 (-0.74%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $26.97 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Exelixis (EXEL) Cabometyx Combo Study Meets Primary Goal

Exelixis'(EXEL) late-stage study evaluating the combination of Cabometyx and Opdivo and Yervoy demonstrates significant improvement in progression-free survival at the primary analysis.

Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies

Exelixis (EXEL) teams up with Ryvu Therapeutics to develop novel STING agonist-based targeted cancer therapies.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Exelixis (EXEL) Outperforms Industry in 1H22: What Lies Ahead?

Exelixis (EXEL) outperforms the industry in the year so far on Cabometyx performance and pipeline progress.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Exelixis (EXEL) Begins Study on XL092 Combo in Colorectal Cancer

Exelixis (EXEL) starts the phase III STELLAR-303 study evaluating XL092 in combination with atezolizumab as compared to regorafenib for treating patients with metastatic colorectal cancer.

Exelixis (EXEL), BioInvent Tie Up for Immuno-Oncology Therapies

Exelixis (EXEL) looks to expand its biotherapeutics development pipeline by using BioInvent's proprietary immuno-oncology screening platform and antibody library.

Why Is Exelixis (EXEL) Down 3.1% Since Last Earnings Report?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Exelixis (EXEL) Announces Results From Phase II HNSCC Study

Exelixis (EXEL) phase II study evaluating Cabometyx in combination with Keytruda in patients with recurrent or metastatic head and neck squamous cell carcinoma meets primary goal.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates

Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.

Exelixis (EXEL) Tops Q1 Earnings Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of 50% and 6.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Kanishka Das headshot

Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More

Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.

Why Exelixis (EXEL) Might Surprise This Earnings Season

Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's How Much You'd Have If You Invested $1000 in Exelixis a Decade Ago

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Exelixis (EXEL) Outperforms Industry YTD: What Lies Ahead?

Exelixis (EXEL) gains 25% in the year so far on strong performance of Cabometyx and encouraging pipeline progress.

Exelixis (EXEL) Initiates Early Stage Study of Lymphoma

Exelixis (EXEL) commences the dose-escalation stage of the phase I study of XL114 in patients with non-Hodgkin's lymphoma.

Here's Why Exelixis (EXEL) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.